ライフサイエンスコーパス: aortic stenosis

1 echocardiograms reported moderate or greater aortic stenosis.

2 d therapy in HR and inoperable patients with aortic stenosis.

3 utcomes in patients with asymptomatic severe aortic stenosis.

4 ng on the medical treatment of patients with aortic stenosis.

5 patients with hypertrophic cardiomyopathy or aortic stenosis.

6 measure disease activity and progression in aortic stenosis.

7 and therapeutic decision-making processes in aortic stenosis.

8 sk operable patients with symptomatic severe aortic stenosis.

9 ercise and hyperemia in patients with severe aortic stenosis.

10 tive aortic regurgitation without coexisting aortic stenosis.

11 odynamic improvement in patients with severe aortic stenosis.

12 catheter aortic-valve replacement (TAVR) for aortic stenosis.

13 on in low LV ejection fraction, low-gradient aortic stenosis.

14 th low LV ejection fraction and low-gradient aortic stenosis.

15 omatic and asymptomatic patients with severe aortic stenosis.

16 e implantation for symptomatic severe native aortic stenosis.

17 ement (TAVR) revolutionized the treatment of aortic stenosis.

18 andard treatment for treatment of inoperable aortic stenosis.

19 with low LV ejection fraction, low-gradient aortic stenosis.

20 freedom from heart failure in patients with aortic stenosis.

21 concept in the care of patients with severe aortic stenosis.

22 as been described as a more advanced form of aortic stenosis.

23 nosis; and low-gradient, normal-flow (LG/NF) aortic stenosis.

24 nt for inoperable or high-risk patients with aortic stenosis.

25 e disease (CAVD) is the most common cause of aortic stenosis.

26 sk, and many intermediate-risk patients with aortic stenosis.

27 natural history and the progression of LG/LF aortic stenosis.

28 replicated the focal calcific structures of aortic stenosis.

29 orbidity and mortality during progression of aortic stenosis.

30 placement (SAVR) for high-risk patients with aortic stenosis.

31 akthrough in the management of patients with aortic stenosis.

32 of age who were undergoing AVR for calcific aortic stenosis.

33 is and predicts adverse clinical outcomes in aortic stenosis.

34 sing novel biomarkers of disease activity in aortic stenosis.

35 n left ventricular biopsies of patients with aortic stenosis.

36 nt option for high-risk patients with severe aortic stenosis.

37 treatment of high-risk patients with severe aortic stenosis.

38 with poor prognosis in patients with severe aortic stenosis.

39 cal (DFM) system for the treatment of severe aortic stenosis.

40 igh- or intermediate-risk surgery for severe aortic stenosis.

41 ld not be made because of concomitant severe aortic stenosis.

42 n is associated with an adverse prognosis in aortic stenosis.

43 ent (TAVR) in high-risk patients with severe aortic stenosis.

44 high-risk or inoperable patients with severe aortic stenosis.

45 isease progression in patients with calcific aortic stenosis.

46 and PAD risk factors overlap with those for aortic stenosis.

47 -risk study patients with severe symptomatic aortic stenosis.

48 e PET/MRI and PET/CT data of 6 patients with aortic stenosis.

49 cision making, and survival in patients with aortic stenosis.

50 /=60 years across 37 advanced economies have aortic stenosis.

51 management of high-risk patients with severe aortic stenosis.

52 BPs increased risk in patients with moderate aortic stenosis.

53 eters for defining high risk in asymptomatic aortic stenosis.

54 burden in patients with asymptomatic severe aortic stenosis.

55 e disease (CAVD) is the most common cause of aortic stenosis.

56 size for outcome prediction in asymptomatic aortic stenosis.

57 001), whereas women were more likely to have aortic stenosis (34.5% versus 44.1%, P<0.001).

58 Eight patient-specific models of severe aortic stenosis (6 tricuspid and 2 bicuspid) were create

59 on (622 [33.1%] vs 57 [24.1%], P < .001) and aortic stenosis (728 [38.7%] vs 51 [21.5%], P < .001).

60 0.18 to 0.46) and was not observed for LG/LF aortic stenosis (adjusted HR: 0.75; 95% CI: 0.14 to 4.05

61 enosis was close to that of mild-to-moderate aortic stenosis (adjusted HR: 0.96; 95% CI: 0.58 to 1.53

62 going TAVI, 433 (71.4%) patients with severe aortic stenosis and a preprocedural right heart catheter

63 ated trial in high-risk patients with severe aortic stenosis and an anatomy suitable for the transfem

64 ic-valve replacement in patients with severe aortic stenosis and an increased risk of death during su

65 1 high-risk patients with symptomatic severe aortic stenosis and anatomy suitable for treatment with

66 our understanding of the pathophysiology of aortic stenosis and as a biomarker end point in clinical

67 al mechanical intervention for patients with aortic stenosis and concomitant reduced ejection fractio

68 ction fraction, low-gradient (LEF-LG) severe aortic stenosis and concomitant relevant mitral regurgit

69 itoring of patients with asymptomatic severe aortic stenosis and help to validate current guidelines

70 In patients with severe aortic stenosis and high surgical risk, PPM is more freq

71 replacement (SAVR) for patients with severe aortic stenosis and high surgical risk.

72 Patients with severe, symptomatic aortic stenosis and high/intermediate surgical risk were

73 , 2016, 203 patients with severe symptomatic aortic stenosis and increased surgical risk, as determin

74 y used in high-risk patients with coexisting aortic stenosis and LM disease.

75 er LV end-systolic diameter in patients with aortic stenosis and low New York Heart Association class

76 In severe patients with severe aortic stenosis and LV dysfunction, transaortic valve me

77 s regression took 24 months in patients with aortic stenosis and nearly 5 years with aortic regurgita

78 A total of 1767 patients with asymptomatic aortic stenosis and no manifest atherosclerotic disease

79 90 mm Hg in these patients with asymptomatic aortic stenosis and no manifest atherosclerotic disease

80 For patients with asymptomatic severe aortic stenosis and normal left ventricular function, cu

81 tients (ages 75 +/- 12 years) diagnosed with aortic stenosis and preserved EF (>/=50%).

82 In asymptomatic patients with severe aortic stenosis and preserved left ventricular ejection

83 In asymptomatic patients with severe aortic stenosis and preserved left ventricular ejection

84 l history of patients with medically managed aortic stenosis and preserved left ventricular function

85 patients with severe symptomatic inoperable aortic stenosis and randomly assigned (1:1) them to tran

86 ated with a higher prevalence of significant aortic stenosis and regurgitation.

87 current available data on stress testing in aortic stenosis and subsequently summarizes its potentia

88 Depending of the severity of the aortic stenosis and the presence of concomitant heart di

89 d EF was similar to that of mild-to-moderate aortic stenosis and was not favorably influenced by aort

90 Patients had severe aortic stenosis and were at increased surgical risk base

91 aortic stenosis in comparison with moderate aortic stenosis and with high-gradient (HG) aortic steno

92 tion, 817 had aortic regurgitation, 471 with aortic stenosis, and 193 with mild mitral stenosis.

93 ft ventricular hypertrophy, cardio-oncology, aortic stenosis, and ischemic heart disease.

94 tension (PH) frequently coexists with severe aortic stenosis, and PH severity has been shown to predi

95 betes, hypertension, iron deficiency anemia, aortic stenosis, and prior bariatric surgery.

96 e aortic stenosis; HG aortic stenosis; LG/LF aortic stenosis; and low-gradient, normal-flow (LG/NF) a

97 and cardiac catheterization in assessment of aortic stenosis, anesthetic and surgical techniques, as

98 70 patients with BAV undergoing surgery for aortic stenosis (aorta diameter </=45 mm: BAVnon-dil or

99 hirty-nine patients with asymptomatic severe aortic stenosis (aortic valve area <1 cm(2), peak jet ve

100 ctively identified 2017 patients with severe aortic stenosis (aortic valve area<1 cm(2), mean gradien

101 c valve replacement (SAVR) for patients with aortic stenosis are unclear.

102 ation (AVC) load measures lesion severity in aortic stenosis (AS) and is useful for diagnostic purpos

103 Patients with severe aortic stenosis (AS) and paradoxical low flow (PLF) have

104 tic valve area (<1.0 cm(2)) in patients with aortic stenosis (AS) and preserved left ventricular ejec

105 cular (LV) systolic dysfunction and moderate aortic stenosis (AS) are more frequent with advancing ag

106 safety and efficacy in patients with severe aortic stenosis (AS) at extreme risk of surgery treated

107 In patients with severe aortic stenosis (AS) at intermediate surgical risk, trea

108 patients who underwent AVR for degenerative aortic stenosis (AS) between March 2010 and September 20

109 Severe aortic stenosis (AS) can manifest as exertional angina e

110 ) system in patients with severe symptomatic aortic stenosis (AS) in routine clinical practice.

111 Low-flow (LF) severe aortic stenosis (AS) is an independent predictor of mort

112 Aortic stenosis (AS) is characterized as a high-risk ind

113 Calcific aortic stenosis (AS) is characterized by calcium deposit

114 RATIONALE: Calcific aortic stenosis (AS) is characterized by calcium deposit

115 Aortic stenosis (AS) is one of the most common valvular

116 Aortic stenosis (AS) leads to variable stress for the le

117 Severe aortic stenosis (AS) most often presents with reduced ao

118 xed aortic valve disease (MAVD) and isolated aortic stenosis (AS) or aortic regurgitation (AR) has no

119 in moderate to severe and paradoxical severe aortic stenosis (AS) patients with preserved ejection fr

120 in children and young adults with congenital aortic stenosis (AS) to determine the extent of fibrosis

121 We examined 1,154 patients with severe aortic stenosis (AS) who underwent AVR with or without c

122 ter cohort study that enrolled patients with aortic stenosis (AS) who underwent SAVR or TAVR.

123 Patients with severe aortic stenosis (AS) who were deemed too high risk or in

124 pected to result in increasing occurrence of aortic stenosis (AS), but data are limited.

125 resonance (CMR) can detect focal fibrosis in aortic stenosis (AS), suggesting that it might predict h

126 tal outcome have been reported in women with aortic stenosis (AS).

127 tcome of patients with calcific degenerative aortic stenosis (AS).

128 rdiovascular risk factors and development of aortic stenosis (AS).

129 isturbed flow as it occurs, for instance, in aortic stenosis (AS).

130 ed lipoprotein(a) (Lp[a]) is associated with aortic stenosis (AS).

131 clinical outcomes in diabetic patients with aortic stenosis (AS).

132 l aortic valve replacement (SAVR) for severe aortic stenosis (AS).

133 d effective therapy for patients with severe aortic stenosis (AS).

134 le in asymptomatic patients with very severe aortic stenosis (AS); however, the definition of very se

135 ricular tissue was procured in patients with aortic stenosis (AS, n=9) and dilated cardiomyopathy (DC

136 cal AVR (SAVR) for patients with symptomatic aortic stenosis at increased operative risk.

137 Patients with severe aortic stenosis at increased risk for surgery had improv

138 In patients with severe aortic stenosis at increased risk for surgery, self-expa

139 valve found that among patients with severe aortic stenosis at increased risk for surgery, the 1-yea

140 In patients with severe aortic stenosis at increased surgical risk, TAVR was ass

141 (TAVR) for patients with severe symptomatic aortic stenosis at intermediate surgical risk, TAVR volu

142 ternative to surgery in patients with severe aortic stenosis at intermediate surgical risk, with a di

143 l-accepted option for treating patients with aortic stenosis at intermediate to high or prohibitive s

144 rgoing isolated aortic valve replacement for aortic stenosis at Mayo Clinic Hospital in Rochester, Mi

145 ffective in patients with symptomatic severe aortic stenosis at prohibitive risk for surgical valve r

146 2032 intermediate-risk patients with severe aortic stenosis, at 57 centers, to undergo either TAVR o

147 surgical aortic valve replacement for severe aortic stenosis between 2012 and 2014 at our institution

148 Calcific aortic stenosis (cAS) affects 3% of individuals aged >75

149 en presented more often with moderate/severe aortic stenosis compared with men.

150 rticular importance for patients with severe aortic stenosis considering transcatheter aortic valve r

151 Patients with severe aortic stenosis deemed at increased risk for surgery by

152 We evaluated 1023 patients with severe aortic stenosis deemed high or extreme risk for surgery

153 m reviewed all moderate- or greater-severity aortic stenosis echocardiography studies with concomitan

154 from symptomatic patients with LEF-LG severe aortic stenosis even in the presence of moderate or seve

155 live-born infants with a fetal diagnosis of aortic stenosis/evolving hypoplastic left heart syndrome

156 This issue provides a clinical overview of aortic stenosis, focusing on screening, diagnosis, treat

157 tic valve replacement was confined to the HG aortic stenosis group (adjusted HR: 0.29; 95% CI: 0.18 t

158 In asymptomatic patients with severe aortic stenosis, guidelines recommend left ventricular e

159 The definition of severe aortic stenosis has classically and retrospectively been

160 tricular (LV) mass in nonsevere asymptomatic aortic stenosis has not been documented in a large prosp

161 er aortic valve replacement for treatment of aortic stenosis has now become an accepted alternative t

162 ately one third of patients with symptomatic aortic stenosis have reduced left ventricular ejection f

163 , was significantly associated with incident aortic stenosis (hazard ratio [HR] per mmol/L, 1.28; 95%

164 were divided into 4 groups: mild-to-moderate aortic stenosis; HG aortic stenosis; LG/LF aortic stenos

165 ted with an increase in the risk of incident aortic stenosis (HR per mmol/L, 1.51; 95% CI, 1.07-2.14;

166 diate-risk patients with severe, symptomatic aortic stenosis in a randomized trial comparing TAVR (pe

167 aortic stenosis and with high-gradient (HG) aortic stenosis in a real-world study, in the context of

168 e sought to investigate the outcome of LG/LF aortic stenosis in comparison with moderate aortic steno

169 ystem in the Treatment of Symptomatic Severe Aortic Stenosis in High Risk and Very High Risk Subjects

170 ystem in the Treatment of Symptomatic Severe Aortic Stenosis in High Risk and Very High Risk Subjects

171 alve replacement (TAVR) for the treatment of aortic stenosis in high- and intermediate-risk patients,

172 % CI, 1.09-1.74; P = .007) and with incident aortic stenosis in MDCS (HR per GRS increment, 2.78; 95%

173 cholesterol (LDL-C) has been associated with aortic stenosis in observational studies; however, rando

174 eart valve (THV) for the treatment of severe aortic stenosis in patients at extreme risk for surgery.

175 e US Food and Drug Administration for severe aortic stenosis in patients who cannot undergo surgery a

176 Current guidelines define severe aortic stenosis in patients with aortic valve area norma

177 y computed tomography in CHARGE and incident aortic stenosis in the MDCS.

178 ter aortic valve replacement (TAVR) to treat aortic stenosis in the United States is growing, yet lit

179 er mmol/L, 1.28; 95% CI, 1.04-1.57; P = .02; aortic stenosis incidence: 1.3% and 2.4% in lowest and h

180 increment, 2.78; 95% CI, 1.22-6.37; P = .02; aortic stenosis incidence: 1.9% and 2.6% in lowest and h

181 r early and midterm outcomes for adults with aortic stenosis, including those at low to intermediate

182 ients with ECG strain (n=21) had more severe aortic stenosis, increased left ventricular mass index,

183 Aortic stenosis is 1 of the most common heart valve dise

184 Aortic stenosis is a common, potentially fatal condition

185 Conventional teaching suggests that aortic stenosis is a degenerative condition whereby "wea

186 Untreated severe aortic stenosis is a progressive disease with a poor pro

187 Untreated, severe, symptomatic aortic stenosis is associated with a dismal prognosis.

188 3 in intermediate-risk patients with severe aortic stenosis is associated with low mortality, stroke

189 Prevalence of calcific aortic stenosis is growing in ageing populations.

190 r aortic valve replacement (TAVR) for severe aortic stenosis is growing rapidly.

191 it is becoming increasingly appreciated that aortic stenosis is instead governed by a highly complex,

192 asymptomatic to symptomatic state in severe aortic stenosis is often difficult to assess.

193 replacement; however, before symptoms occur, aortic stenosis is preceded by a silent, latent phase ch

194 Aortic stenosis is the most frequent valvular heart dise

195 Aortic stenosis is the most frequent valvular heart dise

196 f TR in operable but high-risk patients with aortic stenosis is warranted.

197 groups: mild-to-moderate aortic stenosis; HG aortic stenosis; LG/LF aortic stenosis; and low-gradient

198 Low-gradient severe aortic stenosis (LGSAS) with preserved ejection fraction

199 acement (TAVR) is an effective treatment for aortic stenosis, long-term mortality after TAVR remains

200 Patients with severe aortic stenosis may be deemed inoperable due to technica

201 pressure goals in patients with a history of aortic stenosis may need to be redefined.

202 The new protocol improved aortic stenosis mean gradient agreement between echocard

203 AVI, 113 (18.7%) patients with LEF-LG severe aortic stenosis (mean gradient </=40 mm Hg, aortic valve

204 LV ejection fraction (</=40%), low-gradient aortic stenosis (mean transvalvular gradient <40 mm Hg a

205 art Valves in High Risk Patients With Severe Aortic Stenosis: Medtronic CoreValve Versus Edwards SAPI

206 reported healthy controls and patients with aortic stenosis, mitral regurgitation, and left ventricu

207 d the most common indication for surgery was aortic stenosis (n = 225 [72.6%]).

208 Patients with severe aortic stenosis (n = 61) underwent cardiac magnetic reso

209 least moderate aortic/mitral regurgitation, aortic stenosis, or prior valve surgery (bioprosthesis r

210 apid progression from mild or less to severe aortic stenosis over months, highlighting their need for

211 ated with aortic valve calcium (P = .03) and aortic stenosis (P = .009).

212 6% women) with mild-to-moderate asymptomatic aortic stenosis participating in the Simvastatin Ezetimi

213 R), reoperation to relieve severe prosthetic aortic stenosis (PAS) is increasing.

214 R), reoperation to relieve severe prosthetic aortic stenosis (PAS) is increasing.

215 nic lung disease (CLD) on outcomes of severe aortic stenosis patients across all treatment modalities

216 ment along with calpain were up-regulated in aortic stenosis patients and rats with heart failure.

217 interval [CI]: 1.03 to 2.07), whereas LG/LF aortic stenosis patients did not have an excess mortalit

218 Among high-risk aortic stenosis patients enrolled in the PARTNER I rando

219 -to-moderate aortic stenosis patients, LG/LF aortic stenosis patients had smaller valve areas and str

220 Studies of TAVR in low-flow severe aortic stenosis patients have demonstrated that TAVR has

221 ective subanalysis of high-risk, symptomatic aortic stenosis patients in the PARTNER trial, female su

222 and monitored these changes with PFA-CADP in aortic stenosis patients undergoing transcatheter aortic

223 ild-to-moderate aortic stenosis patients, HG aortic stenosis patients were at higher risk of death (a

224 o 53 months), compared with mild-to-moderate aortic stenosis patients, HG aortic stenosis patients we

225 Compared with mild-to-moderate aortic stenosis patients, LG/LF aortic stenosis patients

226 cipants with ASc had progression to clinical aortic stenosis per year.

227 investigating the role of TAVR in lower-risk aortic stenosis populations, in patients with aortic reg

228 We included 289 patients with asymptomatic aortic stenosis, preserved ejection fraction, and AVA<1.

229 theory, specific medical therapy should halt aortic stenosis progression, reduce its hemodynamic repe

230 th of a child with accelerated bioprosthetic aortic stenosis prompted enhanced surveillance of all su

231 nce of aortic valve calcium and incidence of aortic stenosis, providing evidence supportive of a caus

232 Experiments in the aortic stenosis rabbit model and in left ventricular ass

233 instantaneous changes in shear stress in an aortic stenosis rabbit model and in patients undergoing

234 To ensure that patients with aortic stenosis receive the best treatment option for th

235 n prevalence, valve morphology, dysfunction (aortic stenosis/regurgitation), aortopathy, and complica

236 and need for surgery in patients with LG/LF aortic stenosis remain subjects of intense debate.

237 d treatment of patients with low-flow severe aortic stenosis remains challenging.

238 The management of aortic stenosis rests on accurate echocardiographic diag

239 articipating in the Simvastatin Ezetimibe in Aortic Stenosis (SEAS) study.

240 patients with known bicuspid valve, moderate aortic stenosis, severe mitral regurgitation, severe aor

241 rance status, left ventricular function, and aortic stenosis severity between patients with (n = 202)

242 e area, echocardiographic image quality, and aortic stenosis severity by Doppler and Gorlin methods u

243 led in the multicenter True or Pseudo-Severe Aortic Stenosis study, 126 patients with resting GLS and

244 ave shown that among high-risk patients with aortic stenosis, survival rates are similar with transca

245 m cells (iPSCs) to investigate supravalvular aortic stenosis (SVAS) patients and/or elastin mutant mi

246 In aortic stenosis, therapeutic decision essentially depend

247 relief of valve obstruction in patients with aortic stenosis, there is an independent association bet

248 ndomly assign high-risk patients with severe aortic stenosis to either SAVR or TAVR with a balloon-ex

249 ynamic load may be important in asymptomatic aortic stenosis to identify patients at risk.

250 rom the SEAS trial (Simvastatin Ezetimibe in Aortic Stenosis) to assess what blood pressure (BP) woul

251 of nonsurgical mechanical interventions for aortic stenosis (transcatheter aortic valve replacement)

252 In patients with severe aortic stenosis, transcatheter aortic valve replacement

253 Among 542 patients with symptomatic aortic stenosis treated in the Placement of Aortic Trans

254 d were measured in 2141 patients with severe aortic stenosis treated with TAVR in the PARTNER I trial

255 ut their impact on outcomes in patients with aortic stenosis treated with transcatheter aortic valve

256 ctiveness of SAVR-TAVI Procedures for Severe Aortic Stenosis Treatment (OBSERVANT) study.

257 ctiveness of SAVR-TAVI Procedures for Severe Aortic Stenosis Treatment) trial is an observational pro

258 igh-risk and inoperable patients with severe aortic stenosis undergoing a transcatheter aortic valve

259 predictor of outcome in patients with severe aortic stenosis undergoing aortic valve replacement, ind

260 d 7 nondiabetic cardiomyopathy patients with aortic stenosis undergoing aortic valve replacement.

261 zed clinical trial of patients with calcific aortic stenosis undergoing SAVR at 18 North American cen

262 al trial in higher-risk patients with severe aortic stenosis undergoing TAVI at the University of Lei

263 Among patients with severe aortic stenosis undergoing TAVI, the use of a cerebral p

264 erm mortality rates for patients with severe aortic stenosis undergoing transcatheter aortic valve im

265 In patients with aortic stenosis undergoing transcatheter aortic valve re

266 al of 616 patients age <70 years and without aortic stenosis underwent elective aortic root surgery (

267 Fifteen patients with aortic stenosis underwent repeated 18F-fluoride PET-CT.

268 Treatment of high-risk patients with aortic stenosis using a self-expandable system was assoc

269 t), the mortality risk associated with LG/LF aortic stenosis was close to that of mild-to-moderate ao

270 the excess risk of death associated with HG aortic stenosis was confirmed (adjusted HR: 1.74; 95% CI

271 Life-threatening prosthetic aortic stenosis was detected at a median of 6 months aft

272 dred high surgical risk patients with severe aortic stenosis were evaluated for the primary endpoint.

273 A total of 802 patients with aortic stenosis were randomized to undergo transfemoral

274 qual to III+ aortic regurgitation and severe aortic stenosis were seen in 37% and 10%, respectively.

275 e to severe aortic regurgitation, and severe aortic stenosis were seen in 7%, 18%, and 2%, whereas 91

276 therapy in symptomatic patients with severe aortic stenosis, whereas the management of asymptomatic

277 (SAVR) for patients with symptomatic severe aortic stenosis who are at high risk of perioperative mo

278 ternative to surgery in patients with severe aortic stenosis who are at high surgical risk, less is k

279 is standard therapy for patients with severe aortic stenosis who are at high surgical risk.

280 s of the Lotus valve in patients with severe aortic stenosis who are at high surgical risk.

281 In patients with severe aortic stenosis who are at increased surgical risk, TAVR

282 In patients with severe aortic stenosis who are at increased surgical risk, the

283 ay clinical outcomes in patients with severe aortic stenosis who are at intermediate risk of surgical

284 out comparative outcomes among patients with aortic stenosis who are at intermediate surgical risk.

285 accepted treatment for patients with severe aortic stenosis who are not suitable for surgery.

286 art valve (THV) size in patients with severe aortic stenosis who are suboptimal surgical candidates.

287 ne hundred patients with severe, symptomatic aortic stenosis who had both contrast MDCT and 3D-TEE fo

288 rapidly evolving treatment for patients with aortic stenosis who require valve replacement.

289 l cohort study included patients with severe aortic stenosis who underwent TAVR in the Society of Tho

290 We recruited patients with severe aortic stenosis who were at increased surgical risk as d

291 Patients with severe aortic stenosis who were at increased surgical risk were

292 volved 300 patients with asymptomatic severe aortic stenosis who were seen in the ambulatory Minneapo

293 llion (95% CI, 2.2-4.4) patients have severe aortic stenosis with 1.9 million (95% CI, 1.3-2.6) eligi

294 This review discusses the pathophysiology of aortic stenosis with an emphasis on the emerging importa

295 ibes the epidemiology and pathophysiology of aortic stenosis with heart failure and reduced ejection

296 In this study, the outcome of severe LG/LF aortic stenosis with preserved EF was similar to that of

297 Severe low-gradient, low-flow (LG/LF) aortic stenosis with preserved left ventricular ejection

298 ing TAVR in patients with symptomatic severe aortic stenosis with prohibitive risks for surgery.

299 Renal dysfunction is intricately linked to aortic stenosis, with over 25% patients presenting for t

300 tment of high-risk patients with symptomatic aortic stenosis without open-heart surgery; however, the

301 TA-TAVR included more postdilatations, pure aortic stenosis without regurgitation, and possibly more